Search by Abstract Number Results

Abstract Number: 2393 • ACR Convergence 2025
Improving Clinical Outcomes In SLE Arthritis Trials: Post-Hoc Analysis Of A Prospective Intervention Study
Samuel Wood¹, Khaled Mahmoud², Md Yuzaiful Md Yusof², Philip Conaghan², Elizabeth Hensor² and Ed Vital³, ¹University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Musculoskeletal (MSK) manifestations of SLE are the most frequently assessed domain in clinical trials. Optimal MSK assessment is contested; candidates include the binary or…
Abstract Number: 2393 • ACR Convergence 2024
Demographic Differences in Trends of Systemic Lupus Erythematosus In-hospital Patient Outcomes
Joan Morny¹, Abdultawab Shaka², Terrylyna Baffoe-Bonnie³ and Hafeez Shaka⁴, ¹Piedmont Athens Regional Medical Center, athens, GA, ²Windor University School of Medicine, Saint Kitts and Nevis, U.S. Virgin Islands, ³Medstar Health Union Memorial Hospital, Baltimore, MD, ⁴Stroger Jr Hospital, Chicago, IL
Background/Purpose: The care of patients with Systemic Lupus Erythematosus (SLE) is challenging, and with the emergency of newer disease modifying medications, clinical outcomes in these…
Abstract Number: 2393 • ACR Convergence 2023
CXCL9/IL-6 and MMP3/CD141 Ratio Allow to Discriminate Between Isolated PMR and GCA/PMR Overlap
andre ramon¹, helene Greigert², adrien guilloteau³, claudie cladière⁴, marion ciudad⁵, Sylvain Audia⁶, paul ornetti⁷, jean-Francis Maillefert⁷, Bernard Bonnotte² and Maxime Samson², ¹Department of Rheumatology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Methodological Support Unit (USMR), Dijon-Bourgogne University Hospital, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁶Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France, ⁷Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are frequently overlapping conditions. It is estimated that 16 to 21% of PMR patients have GCA.…
Abstract Number: 2393 • 2019 ACR/ARP Annual Meeting
Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials
Jawad Bilal¹, Irbaz Bin Riaz ², Maryam Sadiq ³, Muhammad Salick ⁴, Yahya Nomaan ⁵, Nusrum Iqbal ⁶, Sandipan Bhattacharjee ⁷, Lary Prokop ⁸ and C. Kent Kwoh ⁷, ¹University of Arizona College of Medicine, Tucson, AZ, ²Mayo Hospital Rochester, Rochester, MN, ³Nishtar Medical College, University of Health Sciences, Lahore, Albany, NY, ⁴Albany Medical Center, Albany, NY, ⁵Phoenix Children's Hospital, Phoenix, AZ, ⁶St Joseph's Hospital, Tucson AZ, Tucson, AZ, ⁷University of Arizona, Tucson, AZ, ⁸Mayo Clinic, Rochestor, MN
Background/Purpose: Importance The efficacy of Janus kinase (JAK) inhibitors is well established across a range of diseases. However, there is a major concern regarding the potential risk of an increased…
Abstract Number: 2393 • 2018 ACR/ARHP Annual Meeting
Is Methotrexate-Induced Nausea in Juvenile Idiopathic Arthritis Influenced By Anxiety or Coping Strategies?
Nini Kyvsgaard¹, Mikael Thastum², Torben Mikkelsen¹, Anne Estmann³ and Troels Herlin¹, ¹Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus N, Denmark, ²Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus C, Denmark, ³Department of Pediatric Rheumatology, H.C. Andersen's Children's Hospital, Odense, Denmark
Background/Purpose: Nausea to low-dose methotrexate (MTX) is a significant clinical challenge in the treatment of juvenile idiopathic arthritis (JIA). There exists a large inter-individual variation…
Abstract Number: 2393 • 2017 ACR/ARHP Annual Meeting
Evaluation of Live Zoster Vaccine in a Subset of Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, and Adalimumab with Methotrexate: Results from a Phase 3b/4 Randomized Trial
Leonard H. Calabrese¹, Carlos Abud-Mendoza², Stephen Lindsey³, Sang Heon Lee⁴, Liza Takiya⁵, Noriko Iikuni⁶, Koshika Soma⁷, Zhen Luo⁸ and Roy Fleischmann⁹, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Hospital Central, San Luis Potosí, Mexico, ³Ochsner Medical Center, Baton Rouge, LA, ⁴Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Shanghai, China, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Patients (pts) with RA are at increased risk for herpes…
Abstract Number: 2393 • 2016 ACR/ARHP Annual Meeting
Medication Use in the Juvenile Systemic Sclerosis Inception Cohort. ARE There Differences in the Diffuse and Limited Subset Patients?
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Valda Stanevicha⁵, Maria Teresa Terreri⁶, Ekaterina Alexeeva⁷, Maria M. Katsicas⁸, Rolando Cimaz⁹, Mikhail Kostik¹⁰, Thomas J. A. Lehman¹¹, Walter A. Sifuentes-Giraldo¹², Vanessa Smith¹³, Flavio Sztajnbok¹⁴, Tadey Avcin¹⁵, Maria Jose Santos¹⁶, Dana Nemkova¹⁷, Cristina Battagliotti¹⁸, Despina Eleftheriou¹⁹, Liora Harel²⁰, Mahesh Janarthanan²¹, Tilmann Kallinich²², Jordi Anton²³, Kirsten Minden², Susan Mary Nielsen²⁴, Kathryn S. Torok²⁵, Yosef Uziel²⁶ and Nicola Helmus¹, ¹Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ²Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ³Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ⁴Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey, ⁵University Childrens Hospital, Riga, Latvia, ⁶Pediatric Rheumatology Unit, Federal University of São Paulo, São Paulo, Brazil, ⁷Rheumatology, Scientific Center of Children's Health, Moscow, Russia, ⁸Service of Immunology & Rheumatology. Hospital de Pediatrìa Prof Dr.Juan.P. Garrahan, MD, Buenos Aires, Argentina, ⁹Pediatrics, University of Firenze, Firenze, Italy, ¹⁰Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ¹¹Chief Div Ped Rheum PTD, Hospital for Special Surgery, New York, NY, ¹²Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹³Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, ¹⁴Pediatric Rheumatology Division, Adolescent Health Care Unit, Universida de do Estado do Rio de Janeiro., Rio de Janeiro, Brazil, ¹⁵University Children's Hospital, Ljubljana, Slovenia, ¹⁶Rheumatology, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ¹⁷Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ¹⁸Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ¹⁹Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ²⁰Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel, ²¹Pediatric Rheumatology, Chennai, India, ²²Charite, University Medicine Berlin, Berlin, Germany, ²³Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ²⁴Rigshospitalet, Copenhagen, Denmark, ²⁵Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ²⁶Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease. Currently there is no data regarding use of medication in jSSc patients. Our project is…
Abstract Number: 2393 • 2015 ACR/ARHP Annual Meeting
Validation of a Web-Based Overlay for Sectoral Scoring of Active Lesions on MRI in Hip Osteoarthritis: Femoral Bone Marrow Lesions Predict Response to Intra-Articular Hyaluronate
Damien Loeuille¹, Nicolas Deseyne², Jacob Jaremko³, Ulrich Weber⁴, Thierry Conrozier⁵, Joel Paschke⁶, Walter Maksymowych⁷, Bernard Maillet⁸ and Henri Lellouche⁹, ¹Rheumatology, Department of Rheumatology, CHRU Vandoeuvre les Nancy, Vandoeuvre les Nancy, France, ²Department of Rheumatology, CHRU Vandoeuvre les Nancy,, Vandoeuvre, France, ³Radiology, Radiology, University of Alberta, Edmonton, AB, Canada, ⁴Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Service de Rhumatologie,CHU de NANCY- Brabois, Vandoeuvre, France, ⁶CaRE Arthritis, Edmonton, AB, Canada, ⁷Medicine, University of Alberta, Edmonton, AB, Canada, ⁸Rheumatology, Clinique Saint Odilon, Moulins, France, ⁹Rheumatology, Hôpital Lariboisière, Paris, France
Background/Purpose: Bone marrow lesions (BML) and synovitis are MRI features that have been associated with symptoms and disease progression in patients with osteoarthritis. The Hip…
Abstract Number: 2393 • 2014 ACR/ARHP Annual Meeting
Similar Improvements in Physical Function, Quality of Life and Work Productivity Among Rheumatoid Arthritis Patients Treated with 2 Different Doses of Methotrexate in Combination with Adalimumab
Gurjit S. Kaeley¹, Midori Jane Nishio², Daryl MacCarter³, Jenny Griffith⁴, Hartmut Kupper⁵, Vishvas Garg⁶ and Jasmina Kalabic⁵, ¹College of Medicine, University of Florida, Jacksonville, FL, ²Diablo Clinical Research, Walnut Creek, CA, ³Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose Methotrexate (MTX) is used in monotherapy or in combination with other DMARDs in the treatment of patients (pts) with rheumatoid arthritis (RA). We evaluated…
Abstract Number: 2393 • 2013 ACR/ARHP Annual Meeting
Involvement Of Transitional T Follicular Like Helper Cells Bearing Triple Phenotypes Of Tfh/Th1/Th17 In The Pathogenesis Of Rheumatoid Arthritis
Shingo Nakayamada¹, Satoshi Kubo², Naoki Yunoue², Maiko Yoshikawa², Shunsuke Fukuyo², Kazuyoshi Saito² and Yoshiya Tanaka², ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: T follicular helper (Tfh) cells are a new subset of T helper cells that regulate B cell function and promote autoantibody production. We previously…
Abstract Number: 2393 • 2012 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Levels Are Not Associated with Subclinical Carotid Atherosclerosis in Patients with Granulomatosis with Polyangiitis but Are Reduced by Glucocorticoids and Statins
Alexandre Wagner S. de Souza¹, Karina de Leeuw², Johanna Westra², Andries J. Smit³, Anne Marijn van der Graaf², Hans L. A. Nienhuis¹, Johan Bijzet², Pieter C. Limburg⁴, Coen A. Stegeman⁵, Marc Bijl⁶ and Cees G.M. Kallenberg², ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Vascular Diseases, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Department of Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ⁵Nephrology, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatology and Clinical Immunology, Martini Hospital, Groningen, Netherlands
Background/Purpose: High mobility group box 1 (HMGB1) is a non-histone DNA binding protein that is passively released by dying cells or actively secreted by immunocompetent…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].